Apellis pulls its IPO as biotech bears rampage on Wall Street

Editas ($EDIT) and BeiGene ($BGNE) may have made it to Nasdaq, but the IPO window isn't open for everyone. Apellis pulled their attempt at going public. The Kentucky biotech had filed for an $86 million offering last fall, as the market began to unwind. Analysts expect that the bar for completing an IPO of any kind has been raised high in the first half of 2016, as biotech shares in particular have come in for a beating. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.